| calcium channel, voltage-dependent, gamma subunit 7 |
CHLORPROMAZINE |
Calcium Channel Type L, Benzothiazepine |
91% |
3.214uM |
2.857uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
CHLORPROMAZINE |
Calcium Channel Type L, Benzothiazepine |
91% |
3.214uM |
2.857uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
CHLORPROMAZINE |
Calcium Channel Type L, Benzothiazepine |
91% |
3.214uM |
2.857uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
CHLORPROMAZINE |
Calcium Channel Type L, Benzothiazepine |
91% |
3.214uM |
2.857uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
CHLORPROMAZINE |
Calcium Channel Type L, Benzothiazepine |
91% |
3.214uM |
2.857uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
CHLORPROMAZINE |
Calcium Channel Type L, Benzothiazepine |
91% |
3.214uM |
2.857uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
CHLORPROMAZINE |
Calcium Channel Type L, Benzothiazepine |
91% |
3.214uM |
2.857uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
CLOZAPINE |
Calcium Channel Type L, Phenylalkylamine |
91% |
.612uM |
.595uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
CLOZAPINE |
Calcium Channel Type L, Phenylalkylamine |
91% |
.612uM |
.595uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
CLOZAPINE |
Calcium Channel Type L, Phenylalkylamine |
91% |
.612uM |
.595uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
CLOZAPINE |
Calcium Channel Type L, Phenylalkylamine |
91% |
.612uM |
.595uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
CLOZAPINE |
Calcium Channel Type L, Phenylalkylamine |
91% |
.612uM |
.595uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
CLOZAPINE |
Calcium Channel Type L, Phenylalkylamine |
91% |
.612uM |
.595uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
CLOZAPINE |
Calcium Channel Type L, Phenylalkylamine |
91% |
.612uM |
.595uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
CLOZAPINE |
Calcium Channel Type L, Phenylalkylamine |
91% |
.612uM |
.595uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
CLOZAPINE |
Calcium Channel Type L, Phenylalkylamine |
91% |
.612uM |
.595uM |
View
|
| 5-hydroxytryptamine receptor 6 |
CARVEDILOL |
Serotonin 5-HT6 |
91% |
1.519uM |
.705uM |
View
|
| dopamine receptor 2 |
CLOZAPINE |
Dopamine D2L |
91% |
.387uM |
.129uM |
View
|
| opioid receptor, sigma 1 |
DEXFENFLURAMINE |
Sigma1 |
91% |
.516uM |
.217uM |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
BENZBROMARONE |
CYP450-2C9 Inhibition |
91% |
.016uM |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
BENZBROMARONE |
CYP450-2C9 Inhibition |
91% |
.016uM |
NoneNone |
View
|
| opioid receptor, kappa 1 |
BENZOTHIAZYL DISULFIDE |
Opiate kappa |
91% |
1.243uM |
.497uM |
View
|
| progesterone receptor |
DESOXIMETASONE |
Progesterone |
91% |
.084uM |
.011uM |
View
|
| progesterone receptor |
DESOXIMETASONE |
Progesterone |
91% |
.084uM |
.011uM |
View
|
| progesterone receptor |
FLUNISOLIDE |
Progesterone |
91% |
.359uM |
.047uM |
View
|
| progesterone receptor |
FLUNISOLIDE |
Progesterone |
91% |
.359uM |
.047uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
FLUPHENAZINE |
Serotonin 5-HT1A |
91% |
1.644uM |
.939uM |
View
|
| adrenergic receptor, alpha 2b |
BENZOTHIAZYL DISULFIDE |
Adrenergic alpha2C |
91% |
1.658uM |
.241uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
BENZOTHIAZYL DISULFIDE |
Adrenergic alpha2C |
91% |
1.658uM |
.241uM |
View
|
| dopamine receptor D3 |
DOXEPIN |
Dopamine D3 |
91% |
1.393uM |
.473uM |
View
|
| prostaglandin-endoperoxide synthase 1 |
MELOXICAM |
Cyclooxygenase COX-1 |
91% |
1.319uM |
NoneNone |
View
|
| prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
MELOXICAM |
Cyclooxygenase COX-1 |
91% |
1.319uM |
NoneNone |
View
|
| adrenergic receptor, alpha 2a |
TRAZODONE |
Adrenergic alpha2A |
91% |
.909uM |
.341uM |
View
|
| adrenergic receptor, alpha 2b |
TOLPERISONE |
Adrenergic alpha2B |
91% |
1uM |
.456uM |
View
|
| adrenergic receptor, alpha 2b |
HALOPERIDOL |
Adrenergic alpha2C |
91% |
1.845uM |
.268uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
HALOPERIDOL |
Adrenergic alpha2C |
91% |
1.845uM |
.268uM |
View
|
| epidermal growth factor receptor |
GENTIAN VIOLET |
Protein Tyrosine Kinase, EGF Receptor |
91% |
.473uM |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, beta |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel associated protein 1 |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel associated protein 2 |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, voltage-gated, type III, beta |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| amiloride-sensitive cation channel 5, intestinal |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, voltage-gated, type III, beta |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, voltage-gated, type I, beta |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, voltage-gated, type IV, alpha polypeptide |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, voltage-gated, type V, alpha polypeptide |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, voltage-gated, type II, beta |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, nonvoltage-gated 1 beta |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, nonvoltage-gated 1, delta |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
VERAPAMIL |
Sodium Channel, Site 2 |
91% |
2.005uM |
1.83uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
TAMOXIFEN |
Calcium Channel Type L, Phenylalkylamine |
92% |
2.042uM |
1.985uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
TAMOXIFEN |
Calcium Channel Type L, Phenylalkylamine |
92% |
2.042uM |
1.985uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
TAMOXIFEN |
Calcium Channel Type L, Phenylalkylamine |
92% |
2.042uM |
1.985uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
TAMOXIFEN |
Calcium Channel Type L, Phenylalkylamine |
92% |
2.042uM |
1.985uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
TAMOXIFEN |
Calcium Channel Type L, Phenylalkylamine |
92% |
2.042uM |
1.985uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
TAMOXIFEN |
Calcium Channel Type L, Phenylalkylamine |
92% |
2.042uM |
1.985uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
TAMOXIFEN |
Calcium Channel Type L, Phenylalkylamine |
92% |
2.042uM |
1.985uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
TAMOXIFEN |
Calcium Channel Type L, Phenylalkylamine |
92% |
2.042uM |
1.985uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
TAMOXIFEN |
Calcium Channel Type L, Phenylalkylamine |
92% |
2.042uM |
1.985uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
TAMOXIFEN |
Calcium Channel Type L, Phenylalkylamine |
92% |
2.042uM |
1.985uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
TAMOXIFEN |
Calcium Channel Type L, Phenylalkylamine |
92% |
2.042uM |
1.985uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
TAMOXIFEN |
Calcium Channel Type L, Phenylalkylamine |
92% |
2.042uM |
1.985uM |
View
|
| adrenergic receptor, beta 3 |
TAMOXIFEN |
Adrenergic beta3 |
92% |
7.703uM |
5.778uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
CISAPRIDE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.53uM |
.515uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
DICYCLOMINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.11uM |
.107uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
DICYCLOMINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
.11uM |
.107uM |
View
|
| glycine receptor, alpha 1 subunit |
IVERMECTIN |
Glycine, Strychnine-Sensitive |
92% |
.3747uM |
.2118uM |
View
|
| glycine receptor, beta subunit |
IVERMECTIN |
Glycine, Strychnine-Sensitive |
92% |
.3747uM |
.2118uM |
View
|
| glycine receptor, alpha 2 subunit |
IVERMECTIN |
Glycine, Strychnine-Sensitive |
92% |
.3747uM |
.2118uM |
View
|
| cholinergic receptor, muscarinic 5 |
IVERMECTIN |
Muscarinic M5 |
92% |
3.608uM |
2.5922uM |
View
|
| Cytochrom P450-2D6 monooxygenase |
LISURIDE |
CYP450-2D6 Inhibition |
92% |
.016uM |
NoneNone |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
ERGOTAMINE |
CYP450-3A4 Inhibition |
92% |
1uM |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
PROMAZINE |
Calcium Channel Type L, Phenylalkylamine |
92% |
1.193uM |
1.16uM |
View
|
| dopamine receptor D3 |
QUETIAPINE |
Dopamine D3 |
92% |
1.1632uM |
.3951uM |
View
|
| adrenergic receptor, alpha 1a |
EPINEPHRINE |
Adrenergic alpha1A |
92% |
.628uM |
.254uM |
View
|
| opioid receptor, sigma 1 |
TERCONAZOLE |
Sigma1 |
92% |
.508uM |
.214uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
SUMATRIPTAN |
Serotonin 5-HT1A |
92% |
.804uM |
.459uM |
View
|
| cholinergic receptor, muscarinic 2 |
PAROXETINE |
Muscarinic M2 |
92% |
.532uM |
.189uM |
View
|
| adrenergic receptor, alpha 2b |
CYPROHEPTADINE |
Adrenergic alpha2C |
92% |
1.275uM |
.185uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
CYPROHEPTADINE |
Adrenergic alpha2C |
92% |
1.275uM |
.185uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
PIPAMAZINE |
Serotonin Transporter |
92% |
.651uM |
.346uM |
View
|
| adrenergic receptor, alpha 2a |
ECONAZOLE |
Adrenergic alpha2A |
92% |
4.325uM |
1.622uM |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
ECONAZOLE |
CYP450-3A4 Inhibition |
92% |
.05uM |
NoneNone |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
MICONAZOLE |
Calcium Channel Type L, Dihydropyridine |
92% |
6.266uM |
4.028uM |
View
|
| ATPase, Na+/K+ transporting, alpha 4 polypeptide |
OUABAIN |
ATPase, Na+/K+ |
92% |
.678uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, alpha 3 polypeptide |
OUABAIN |
ATPase, Na+/K+ |
92% |
.678uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, alpha 2 polypeptide |
OUABAIN |
ATPase, Na+/K+ |
92% |
.678uM |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
THIORIDAZINE |
Calcium Channel Type L, Benzothiazepine |
91% |
.469uM |
.417uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
THIORIDAZINE |
Calcium Channel Type L, Benzothiazepine |
91% |
.469uM |
.417uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
THIORIDAZINE |
Calcium Channel Type L, Benzothiazepine |
91% |
.469uM |
.417uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
THIORIDAZINE |
Calcium Channel Type L, Benzothiazepine |
91% |
.469uM |
.417uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
THIORIDAZINE |
Calcium Channel Type L, Benzothiazepine |
91% |
.469uM |
.417uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
THIORIDAZINE |
Calcium Channel Type L, Benzothiazepine |
91% |
.469uM |
.417uM |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
TANNIC ACID |
CYP450-2C9 Inhibition |
91% |
4.6074uM |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
TANNIC ACID |
CYP450-2C9 Inhibition |
91% |
4.6074uM |
NoneNone |
View
|
| A3 adenosine receptor |
ZAFIRLUKAST |
Adenosine A3 |
91% |
1.363uM |
.77uM |
View
|
| lymphocyte protein tyrosine kinase (mapped) |
BITHIONOL |
Protein Tyrosine Kinase, Lck |
91% |
2.255uM |
NoneNone |
View
|
| adrenergic receptor, alpha 1d (Non-specific probe) |
BENZTROPINE |
Adrenergic alpha1D |
91% |
.052uM |
.026uM |
View
|
| adrenergic receptor, alpha 1a |
CINNARIZINE |
Adrenergic alpha1A |
91% |
1.919uM |
.777uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
PEMOLINE |
Dopamine Transporter |
91% |
.5213uM |
.4142uM |
View
|
| adrenergic receptor, alpha 1b |
FLUNARIZINE |
Adrenergic alpha1B |
91% |
1.096uM |
.606uM |
View
|
| angiotensin 1 converting enzyme 1 |
QUINAPRIL |
Protease, Angiotensin Converting Enzyme |
91% |
4.008uM |
NoneNone |
View
|
| angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
QUINAPRIL |
Protease, Angiotensin Converting Enzyme |
91% |
4.008uM |
NoneNone |
View
|
| adrenergic receptor, alpha 1d (Non-specific probe) |
QUETIAPINE |
Adrenergic alpha1D |
91% |
.0966uM |
.0475uM |
View
|
| opioid receptor, sigma 1 |
TERBINAFINE |
Sigma1 |
91% |
.5602uM |
.2354uM |
View
|
| cholinergic receptor, muscarinic 1 |
TERCONAZOLE |
Muscarinic M1 |
91% |
5.709uM |
1.375uM |
View
|
| arachidonate 15-lipoxygenase, second type |
TERCONAZOLE |
Lipoxygenase 15-LO |
91% |
2.446uM |
NoneNone |
View
|
| arachidonate 15-lipoxygenase |
TERCONAZOLE |
Lipoxygenase 15-LO |
91% |
2.446uM |
NoneNone |
View
|
| arachidonate 15-lipoxygenase |
TERCONAZOLE |
Lipoxygenase 15-LO |
91% |
2.446uM |
NoneNone |
View
|
| adrenergic receptor, alpha 2a |
SEMUSTINE |
Imidazoline I2, Central |
91% |
1.615uM |
1.077uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
SEMUSTINE |
Imidazoline I2, Central |
91% |
1.615uM |
1.077uM |
View
|
| adrenergic receptor, alpha 1a |
PENTAMIDINE |
Adrenergic alpha1A |
91% |
1.212uM |
.491uM |
View
|
| adrenergic receptor, alpha 1d (Non-specific probe) |
METERGOLINE |
Adrenergic alpha1D |
91% |
.136uM |
.067uM |
View
|
| cholinergic receptor, muscarinic 4 |
PROCHLORPERAZINE |
Muscarinic M4 |
91% |
1.363uM |
.19uM |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
FLUVASTATIN |
CYP450-2C9 Inhibition |
91% |
.4uM |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
FLUVASTATIN |
CYP450-2C9 Inhibition |
91% |
.4uM |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
CYPROHEPTADINE |
Adrenergic, Norepinephrine Transporter |
91% |
.564uM |
.559uM |
View
|
| opioid receptor, sigma 1 |
NOVARTIS P-38 INHIBITOR |
Sigma1 |
91% |
.7951uM |
.3342uM |
View
|
| adenosine A2a receptor |
ECONAZOLE |
Adenosine A2A |
91% |
14.616uM |
8.206uM |
View
|
| Cytochrom P450-1A2 monooxygenase |
ECONAZOLE |
CYP450-1A2 Inhibition |
91% |
.3uM |
NoneNone |
View
|
| dopamine receptor D4 |
MICONAZOLE |
Dopamine D4.2 |
91% |
15.27uM |
5.354uM |
View
|
| melanocortin 4 receptor |
MICONAZOLE |
Melanocortin MC4 |
91% |
12.448uM |
11.97uM |
View
|
| prostaglandin-endoperoxide synthase 2 |
INDOMETHACIN |
Cyclooxygenase COX-2 |
91% |
.84uM |
NoneNone |
View
|
| prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
INDOMETHACIN |
Cyclooxygenase COX-2 |
91% |
.84uM |
NoneNone |
View
|
| cholinergic receptor, muscarinic 4 |
DEXCHLORPHENIRAMINE |
Muscarinic M4 |
91% |
1.976uM |
.276uM |
View
|
| adrenergic receptor, alpha 2b |
DEXCHLORPHENIRAMINE |
Adrenergic alpha2B |
91% |
4.607uM |
2.103uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
SULCONAZOLE |
Serotonin 5-HT2B |
91% |
3.02uM |
1.922uM |
View
|
| adrenergic receptor, alpha 2a |
SULCONAZOLE |
Adrenergic alpha2A |
91% |
4.043uM |
1.516uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2A |
LY-294002 |
Serotonin 5-HT2A |
91% |
2.796uM |
.799uM |
View
|
| progesterone receptor |
MEDROXYPROGESTERONE |
Progesterone |
91% |
.711uM |
.093uM |
View
|
| thromboxane A synthase 1 |
HEXACHLOROPHENE |
Thromboxane Synthetase |
91% |
3.087uM |
NoneNone |
View
|
| thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) |
HEXACHLOROPHENE |
Thromboxane Synthetase |
91% |
3.087uM |
NoneNone |
View
|